NuvOx is a clinical-stage biopharmaceutical company developing NanO2, an intravenous oxygen therapeutic designed to treat diseases driven by hypoxia. NanO2 is a nano-scale fluorocarbon emulsion that converts from liquid to gas at body temperature, carrying and delivering oxygen to oxygen-deprived tissues. Because its particles are significantly smaller than red blood cells, NanO2 can penetrate tissue where blood flow is restricted. NuvOx is developing NanO2 across three primary indications: acute ischemic stroke to preserve brain tissue, glioblastoma multiforme as a radiosensitizer to enhance radiation therapy, and acute respiratory distress syndrome to improve blood oxygenation. As a pre-commercial company, NuvOx has no approved products and generates revenue primarily through government research grants. The company relies on clinical partnerships and investigator-sponsored studies to advance its clinical pipeline. NuvOx plans to commercialize NanO2 by selling directly to hospitals or collaborating with third-party partners upon regulatory approval.